The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population
JNCI: Journal of the National Cancer Institute · 01.10.2025 · 117 (10) · 2029-2043
DOI: 10.1093/jnci/djaf155 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 03.07.2025. Verfasst von Margherita Rimini und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Cisplatin, gemcitabine, and durvalumab combination is a standard first-line treatment for advanced biliary tract cancer. This study aimed to assess the impact of genetic alterations on outcomes in patients with advanced biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab in real-world clinical practice.
Methods
Patients with unresectable, locally advanced, or metastatic biliary tract cancer treated with cisplatin and gemcitabine plus durvalumab across 39 centers in 11 countries in Europe, the United States, and Asia were included in this analysis.
Results
The cohort included 513 patients with advanced biliary tract cancer. The 5 most frequently altered genes were TP53 (22.1%), KRAS (13.7%), CDKN2A/B (13.6%), ARID1A (12.2%), and IDH1 (9.2%). In multivariate analysis, SMAD4 mutations were associated with improved progression-free survival (PFS) (hazard ratio [HR] = 0.49, P = .018) and overall survival (HR = 0.11, P = .023), while TP53 mutations were linked to worse PFS (HR = 1.62, P = .0047) and TERT mutations to worse overall survival (HR = 8.92, P = .0012). No other genomic alterations were statistically associated with outcomes. Subgroup analysis showed that TP53 mutations negatively affected PFS and overall survival in intrahepatic cholangiocarcinoma, while KRAS mutations were associated with poorer PFS in extrahepatic cholangiocarcinoma. No gene alterations were linked to outcomes in gallbladder cancer.
Conclusions
This large-scale analysis, with comprehensive molecular profiling, supports the positive prognostic impact of SMAD4 mutations for PFS and overall survival and highlights the negative prognostic roles of TP53 (PFS) and TERT (overall survival) mutations, providing valuable insights for personalized treatment strategies in biliary tract cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma 200-00128, Italy.
- Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
- Clinical Oncology Unit, Careggi University Hospital, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
ORCID-Profile: Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Federico Rossari, Frederik Peeters, Tiziana Pressiani, Jessica Lucchetti, Jin Won Kim, Oluseyi Abidoye, Ilario Giovanni Rapposelli, Fabian Finkelmeier, Guido Giordano, Federico Nichetti, Hong Jae Chon, Aitzaz Qaisar, Chiara Pirrone, Florian Castet, Emiliano Tamburini, Alessandro Parisi, Mario Scartozzi, Antonio Avallone, Salvatore Corallo, Marta Schirripa, Ester Oneda, Monica Verrico, Jorge Adeva, Stephen L Chan, Gian Paolo Spinelli, Nicola Personeni, Ingrid Garajova, Maria Grazia Rodriquenz, Ricardo Roque, Giovanni Farinea, Francesca Salani, Antonio De Rosa, Silvia Camera, Masafumi Ikeda, Jeroen Dekervel, Monica Niger, Minsu Kang, Tanios Bekaii-Saab, Luca Esposito, Alessandra Boccaccino
Zitieren
APA
Rimini, M., Fornaro, L., Lo Prinzi, F., Rizzato, M. D., Saborowski, A., Antonuzzo, L., Rossari, F., Satake, T., Peeters, F., Vivaldi, C., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., Giordano, G., Nichetti, F., …, & Boccaccino, A. (2025). The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population. JNCI: Journal of the National Cancer Institute, 117(10), 2029-2043. https://doi.org/10.1093/jnci/djaf155
Vancouver
Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, et al. The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population. JNCI: Journal of the National Cancer Institute. 2025;117(10):2029-2043. doi:10.1093/jnci/djaf155
BibTeX
@article{Rimini2025,
author = {Rimini, Margherita and Fornaro, Lorenzo and Lo Prinzi, Federica and Rizzato, Mario Domenico and Saborowski, Anna and Antonuzzo, Lorenzo and Rossari, Federico and Satake, Tomoyuki and Peeters, Frederik and Vivaldi, Caterina and Pressiani, Tiziana and Lucchetti, Jessica and Kim, Jin Won and Abidoye, Oluseyi and Rapposelli, Ilario Giovanni and Tamberi, Stefano and Finkelmeier, Fabian and Giordano, Guido and Nichetti, Federico and Jae Chon, Hong and Braconi, Chiara and Qaisar, Aitzaz and Pirrone, Chiara and Castet, Florian and Tamburini, Emiliano and Yoo, Changhoon and Parisi, Alessandro and Diana, Anna and Scartozzi, Mario and Prager, Gerald W and Avallone, Antonio and Corallo, Salvatore and Schirripa, Marta and Kim, Il Hwan and Perkhofer, Lukas and Oneda, Ester and Verrico, Monica and Adeva, Jorge and Chan, Stephen L and Spinelli, Gian Paolo and Personeni, Nicola and Garajova, Ingrid and Rodriquenz, Maria Grazia and Leo, Silvana and Alvim, Cecilia Melo and Roque, Ricardo and Farinea, Giovanni and Salani, Francesca and De Rosa, Antonio and Lavacchi, Daniele and Camera, Silvia and Ikeda, Masafumi and Dekervel, Jeroen and Niger, Monica and Balsano, Rita and Tonini, Giuseppe and Kang, Minsu and Bekaii-Saab, Tanios and Esposito, Luca and Boccaccino, Alessandra},
title = {The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {10},
pages = {2029--2043},
doi = {10.1093/jnci/djaf155}
}
EUVIMED